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ABSTRACT: The functionalized amino acid, lacosamide ((R)-2), and
the α-aminoamide, saﬁnamide ((S)-3), are neurological agents that
have been extensively investigated and have displayed potent
anticonvulsant activities in seizure models. Both compounds have
been reported to modulate voltage-gated sodium channel activity. We
have prepared a series of chimeric compounds, (R)-7−(R)-10, by
merging key structural units in these two clinical agents, and then
compared their activities with (R)-2 and (S)-3. Compounds were
assessed for their ability to alter sodium channel kinetics for
inactivation, frequency (use)-dependence, and steady-state activation
and fast inactivation. We report that chimeric compounds (R)-7−(R)-
10 in catecholamine A-diﬀerentiated (CAD) cells and embryonic rat
cortical neurons robustly enhanced sodium channel inactivation at
concentrations far lower than those required for (R)-2 and (S)-3, and
that (R)-9 and (R)-10, unlike (R)-2 and (S)-3, produce sodium channel frequency (use)-dependence at low micromolar
concentrations. We further show that (R)-7−(R)-10 displayed excellent anticonvulsant activities and pain-attenuating properties
in the animal formalin model. Of these compounds, only (R)-7 reversed mechanical hypersensitivity in the tibial-nerve injury
model for neuropathic pain in rats.
KEYWORDS: Chimeric compounds, functionalized amino acids (lacosamide), α-aminoamides (saﬁnamide), sodium channel activity,
antiseizure activity, antinociception activity
We have reported a novel chimeric compound, (R)-1,1derived by merging key structural units present in
lacosamide2 ((R)-N-benzyl 2-N-acetamido-3-methoxypropiona-
mide, (R)-2) and saﬁnamide3 ((S)-2-(4′-((3″-ﬂuoro)-
benzyloxy)benzyl)aminopropionamide, (S)-3), two neurolog-
ical agents that have been extensively investigated (Figure 1).
Lacosamide is the archetypal functionalized amino acid (FAA)
and is a ﬁrst-in-class antiseizure drug (ASD) used for the
adjunctive and monotherapy treatment of partial-onset seizures
in adults.4 Saﬁnamide is a principal example of the class of
compounds dubbed α-aminoamide (AAA) and has pharmaco-
logical properties relevant to the treatment of Parkinson’s
disease.5,6 In (R)-1, we retained the (R)-N-benzyl 2-acetamido-
3-methoxypropionamide (A) unit found in (R)-2 and the N-
(4′-((3″-ﬂuoro)benzyloxy)benzylamino (B) moiety in (S)-3
(Figure 1). Both (R)-2 and (S)-3 modulated neuronal
hyperexcitability by inhibiting voltage-gated sodium channel
(VGSC) activity.7−10 In merging these structural units from
(R)-2 and (S)-3, we sought compounds with improved and
broader functions.
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Utilizing patch-clamp electrophysiology in the whole-cell
conﬁguration, we observed that (R)-1 enhanced the transition
of sodium channels in a mouse neuron model cell line,
catecholamine A-diﬀerentiated (CAD) cells, into inactivated
states and also produced frequency (use)-dependent inhib-
ition.11 Compound (R)-1 exhibited eﬀective anticonvulsant
activity in the maximal electroshock seizure12 (MES) test in
mice (intraperitoneal, ip), but its activity was not better than
that of either (R)-22,13 or (S)-35 (MES ED50 (mice, ip, mg/kg):
(R)-1, 13, (R)-2, 4.5, (S)-3, 4.1).1 Cellular and anticonvulsant
activities similar to (R)-1 were observed for the nonﬂuorinated
(R)-1 analogue, (R)-4, and the two (R)-1 ﬂuorine-regioisomers,
(R)-5 and (R)-6.1,11 When (R)-1 was tested in the rat tibial-
nerve injury (TNI) model of neuropathic pain,14 a single ip
administration completely reversed mechanical hypersensitiv-
ity.11
The cellular and animal pharmacological proﬁle for (R)-1
steered us to prepare (R)-7−(R)-10, four chimeric compounds
that diﬀered from (R)-1 in the substitution pattern of the
terminal benzyloxy (OCH2C6H4X) moiety. We evaluated the
compounds by voltage-clamp electrophysiology in CAD cells15
and rat embryonic cortical neurons and compared their cellular
properties with the parent compounds, (R)-2 and (S)-3, to
determine if the structural units (A and B, Figure 1) in the
parent compounds endow sodium channel-mediating proper-
ties. We show that (R)-7−(R)-10 enhanced transition of
sodium channels to inactivated conformational states at
concentrations far lower than those required by (R)-2 and
(S)-3 and that several chimeric compounds produced frequency
(use)-dependent inhibition at low micromolar concentrations.
We also report excellent activity for (R)-7−(R)-10 in the MES
and 6 Hz psychomotor16 animal seizure models and that many
of the chimeric compounds displayed activity in the formalin
pain model17 in mice. However, only (R)-7 reversed
mechanical hypersensitivity in the TNI model in rats.
■ RESULTS
Chimeric Compound Selection. Our earlier studies
showed that chimeric compounds (R)-1 and (R)-5, each of
which contains an electron-withdrawing ﬂuorine group in the
terminal aromatic ring, modulated Na+ channel properties11
and exhibited excellent anticonvulsant activities.1 Thus, we
prepared the four benzyloxy analogues in which either a
chlorine ((R)-7, (R)-8) or a triﬂuoromethoxy-group ((R)-9,
(R)-10) was positioned at either the 3″- or 4″-aryl site.
Chemistry. Compounds (R)-7−(R)-10 were all prepared
by the general procedure described in Scheme 1. Using the
mixed anhydride coupling (MAC) method,18 we coupled (R)-
N-tert-butoxycarbonyl-D-serine ((R)-24) with the substituted
(4-(benzyloxy)phenyl)methanamines 20−23 to give amides
(R)-25−(R)-28, respectively, without racemization of the C(2)
chiral center. The substituted ((benzyloxy)phenyl)-
methanamines were prepared by treating 4-cyanophenol (11)
with the substituted benzyl bromides 12−15 and K2CO3 in
acetone to provide nitriles 16−19,19,20 respectively, which were
then reduced (LiAlH4) to give amines 20−23. Methylation
(CH3I, Ag2O) of the serine hydroxyl group in (R)-25−(R)-28
yielded ethers (R)-29−(R)-32, respectively. Removal of the
tert-butoxycarbonyl group in (R)-29−(R)-32 with acid (HCl/
dioxane) and then acetylation (AcCl, Et3N) gave the desired
products (R)-7−(R)-10, respectively. The enantiomeric purities
of (R)-7−(R)-10 were assessed by a 1H NMR method using
the chiral resolving agent, (R)-(−)-mandelic acid.21 Parent
compound (S)-3 was prepared as previously reported.3 The
Methods section provides the synthetic procedures and
physical, spectral, and analytical properties for the ﬁnal
compounds evaluated in the pharmacological studies. The
Supporting Information gives similar data for all the synthetic
intermediates and ﬁnal products.
Whole-Cell, Patch-Clamp Electrophysiology. We have
previously reported that (R)-1 altered sodium channel kinetics
in CAD cells by enhancing the transition to inactivated states in
response to protocols that estimate both the fast- and the slow-
inactivated states. Compound (R)-1 also limited sodium
channel current density in frequency (use)-dependent fash-
ion.11 All three proceses are well studied kinetic properties of
sodium channels that collectively can exert control over
neuronal hyperexcitability.7−9,22 Accordingly, we examined if
the same sodium channel properties were aﬀected by (R)-7−
(R)-10 and compared these activities with our previous ﬁndings
with compounds (R)-1, (R)-4, and (R)-511 and with the parent
compounds (R)-29,11,23 and (S)-3. In the earlier studies, we
used CAD cells because they express endogenous tetrodotoxin-
sensitive sodium channels well suited for the study of activation
and inactivation kinetics15 and are likely composed of a
majority of NaV1.7 channels with very minor contributions by
NaV1.1, NaV1.3, and NaV1.9 channels.
9,24,25 We established that
(R)-2-mediated eﬀects on CAD cell sodium channels9 are
similar to those reported for cultured neurons and for mouse
N1E-115 neuroblastoma cells.7 Importantly, the NaV1.7
channel is involved in conducting pain impulses in peripheral
nerves, and loss of NaV1.7 function restricts pain in rodent
Figure 1. Structures of (R)-1, lacosamide ((R)-2), and saﬁnamide
((S)-3). Box A represents lacosamide ((R)-2) derived component of
(R)-1, and box B represents saﬁnamide ((S)-3) derived component of
(R)-1.
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models of inﬂammatory and neuropathic pain.26 We also
evaluated (R)-7−(R)-10 on VGSCs in rat embryonic cortical
neurons. These central nervous system (CNS) neurons express
a subset of VGSC isoforms, NaV1.1, NaV1.2, NaV1.3, and
NaV1.6;
27 dysregulation as well as mutations in these isoforms
have been reported in human epilepsies.28
A. CAD Cells. In Figures 2−4, we illustrate the eﬀects of (R)-
7−(R)-10 in CAD cells on sodium channel biophysical
properties of inactivation, steady-state activation and fast
inactivation, and frequency (use)-dependence. We have
previously reported the eﬀects of (R)-2 on these sodium
channel properties in CAD cells9,11,23 and provide herein the
corresponding results for (S)-3 (Figure 5). To test the ability of
(R)-7−(R)-10 and (S)-3 to modulate transition to an
inactivated state, CAD cells were subjected to conditioning
prepulses ranging from −120 to +20 mV in 10 mV increments
for 5 s.9,11,23 During this conditioning pulse, channels enter
both slow- and fast-inactivated states. To estimate slow-
inactivated current, a pulse to −120 mV was given for 150
ms to allow fast-inactivated channels to recover. A 15 ms
depolazrization to 0 mV is then applied to test the available
fraction of current (Figure 2A). Diﬀerences in available current
between control and compound treated cells represent altered
sodium channel inactivation via either altered transition into
slow-inactivated state or block of fast-inactivated channels with
slow oﬀ kinetics.29,30 Unseparated in this study, these two
possibilities have the same physiological outcome on current
generation by aﬀected channels. Representative traces (at −120
and −50 mV) from CAD cells treated with 0.1% DMSO
(control) or 10 μM (R)-7−(R)-10 are plotted in Figure 2B.
The −50 mV potential is strongly aﬀected by compounds that
mediate slow inactivation kinetics and is within a range of
voltages that aﬀect several channel and cellular properties
including inactivation,30−32 resting membrane potential and
action potential ﬁring,33,34 as well as activation and inactivation
kinetics.31,35 To determine the relative extent to which each
compound facilitated this inactivation kinetics, we graphed the
−50 mV data points for several concentrations and calculated
the IC50 inactivation value (Figure 2C−F). Compared with our
recently reported IC50 value of 85 μM for (R)-2,
9,11 the
inactivation protocol IC50 values for the newly prepared
chimeric compounds were 250−610-fold lower (IC50 (μM):
(R)-7, 0.34; (R)-8, 0.31; (R)-9, 0.24; (R)-10, 0.14). The IC50
values for the unsubstituted ((R)-4) and the ﬂuorine-
substituted chimeric compounds ((R)-1 and (R)-5) were
between 1.6 and 1.7 μM (IC50 (μM): (R)-1, 1.7; (R)-4, 1.6;
(R)-5, 1.6).11 When we tested (S)-3, we determined a 13 μM
IC50 value for the inactivation protocol (Figure 5C), a value
between that of chimeric compounds (R)-7−(R)-10 and (R)-2.
In addition, (R)-7−(R)-10 displayed enhanced eﬃcacy over
(R)-2 and (S)-3 (i.e., the maximal transition to inactivated
channel state was increased). Together, these ﬁndings indicated
that appendage of the substituted benzyloxy moiety
(OCH2C6H4X), similar to that found in (S)-3 to (R)-2,
provided compounds that powerfully promoted sodium
channel inactivation transition and that the terminal aryl
substituent X aﬀected the degree of inactivation facilitation.
We next asked if (R)-7−(R)-10 and (S)-3 compounds
mediate the steady-state fast inactivation property of sodium
channels. A fast-inactivated state was induced by the previously
Scheme 1. Synthesis of (R)-7−(R)-10
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described elecrophysiological voltage protocol (Figure 3A, left)
and ﬁtted to Boltzmann equation which was then used to derive
the V1/2 value of fast inactivation and k, a slope value of the
curve (Figure 3B−E).9,11,23 The V1/2 value for inactivation for
0.1% DMSO (control)-treated cells was −68.8 ± 0.4 mV (n =
4), which diﬀered from that of (R)-9 (10 μM)-treated cells
(−76.5 ± 0.6 mV; n = 5; p < 0.05; Student’s t test; Figure 3D).
The ∼7.7 mV hyperpolarizing shift observed in the presence of
(R)-9 was the only V1/2 value signiﬁcantly diﬀerent from
control (Figure 3B, C, F) (p < 0.05 vs 0.1% DMSO control;
Student’s t test). By comparison, we previously observed that
(R)-1 aﬀected sodium channel fast inactivation11 but that (R)-2
did not.9,11,23 For (S)-3, compared with control, we observed a
pronounced concentration-dependent hyperpolarizing change
in the V1/2 value of fast inactivation reaching a maximum at
∼21.6 mV in the presence of 200 μM (S)-3 (Figure 5F).
Similarly, we observed that (R)-4 induced a shift of ∼4.2 mV
(with 10 μM) and ∼19.7 mV (with 100 μM), and that (R)-5
induced a shift of ∼8.0 mV (with 10 μM) and ∼14.1 mV (with
100 μM), compared with control (∼0.1% DMSO). We found
with the chimeric compounds (R)-7−(R)-10, VGSC steady-
state activation properties (Figure 3A, right) were unchanged
from 0.1% DMSO (control) (Figure 3B−E).
Lastly, we tested if (R)-7−(R)-10 and (S)-3 could cause
frequency (use)-dependent Na+ current block. The speciﬁc
property of frequency- or use-dependent block is beneﬁcial for
ASDs because it allows for potent sodium channel block during
periods of high-ﬁring frequency (i.e., during seizure episodes),
but not during periods of low-ﬁring frequency.22 We previously
showed for (R)-2, and several structurally related compounds,
that concentrations from 5−8-fold greater than the determined
inactivation IC50 value were needed to observe frequency (use)-
inhibition in CAD cells.23 Here, compounds were tested at 10
μM, a concentration ≥29-fold higher than their inactivation
IC50 value, to guarantee observation of use-dependency if the
property is present. To monitor this property, 30 repeated test
pulses were applied at 10 Hz (Figure 4A inset).7,9,23 The
diﬀerence in available current was measured by comparing peak
current recorded during each pulse as a fraction of the initial
pulse current ((pulsen)/(pulse1)). Compounds (R)-9 and (R)-
10 revealed frequency (use)-dependent inhibition of Na+
currents (Figure 4B). Currents at the ﬁnal pulse in cells
treated with (R)-9 measured ∼28% lower than 0.1% DMSO
Figure 2. Eﬀects of the chimeric compounds (R)-7−(R)-10 on inactivation state of Na+ currents in CAD cells. (A) Inactivation voltage protocol.
Currents were elicited by 5 s prepulses between −120 and −20 mV and then fast-inactivated channels were allowed to recover for 150 ms at a
hyperpolarized pulse to −120 mV. The fraction of channels available at 0 mV was analyzed. (B) Representative current traces from CAD cells
without (control, 0.1% DMSO) or in the presence of 10 μM of the compounds as indicated. The red and blue traces represent the currents evoked at
−120 and −50 mV (arrows), respectively (also highlighted in the voltage protocol as a dashed line). (C−F) Summary of inactivation curves for CAD
cells treated with 0.1% DMSO (control) or various concentrations of the compounds as indicated. The concentrations of half maximal eﬀect for −50
mV conditioning pulse (see text for detailed explanations), the IC50, are indicated in boxes within each panel. Data are from 4 to 8 cells per
condition. Some error bars are smaller than the symbols.
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control, while the current at the last pulse in cells treated with
(R)-10 was ∼39% lower. As a comparsion, our previous study
showed 40% reduction of Na+ currents in cells treated with
(R)-1 (8.5 μM) and ∼8.8% reduction with (R)-2 (100 μM).23
When, CAD cells were treated with 100 μM (S)-3, we observed
a modest level of inhibition (∼13%) of Na+ current (Figure 5I).
B. Cortical Neurons. The eﬀects of (R)-7−(R)-10 in rat
embryonic cortical neurons on inactivation, steady-state
activation and fast inactivation, and frequency (use)-depend-
ence are reported in Figures 6−8. We add to these ﬁgures,
newly measured values for the chimeric compounds (R)-1 and
(R)-4 − (R)-6 and the two parent compounds (R)-2 and (S)-3.
The cortical embryonic neurons were grown for 7−10 days in
vitro and then examined using previously described protocols.36
In contrast to CAD cells that express predominantly one
isoform of sodium channels (NaV1.7),
9,24,25 cortical neurons
express varying amounts of NaV1.1−1.3 and NaV1.6.
27
Determining the strict contribution of each current type in
the additional presence of (R)-7−(R)-10 was not practical, as
any results may be confounded by interactions between
blockers of various NaV channels and the compounds
themselves. We therefore presume the kinetics and measured
peaks represent the totality of each CNS NaV isoform, and it is
this total recorded current that will be compared between
experimental conditions. The compounds were tested only at
10 μM due to experimental constraints largely governed by
cortical neuron viability in patch-clamp conditions and limited
obtainability of culture preparations.
First, we evaluated the ability of the chimeric compounds
(R)-1 and (R)-4−(R)-10 to promote an inactivated con-
Figure 3. Eﬀects of the chimeric compounds (R)-7−(R)-10 on fast
inactivation and steady-state activation states of Na+ currents in CAD
cells. (A) Fast inactivation (left) and steady-state activation (right)
voltage protocols. (B−E) Representative Boltzmann ﬁts for steady-
state fast inactivation and steady-state activation for currents recorded
from CAD cells treated with 0.1% DMSO (control) and various
concentrations of the indicated compounds are graphed. Values for
V1/2, the voltage of half-maximal inactivation and activation, and the
slope factors (k) were derived from Boltzmann distribution ﬁts to the
individual recordings and averaged to determine the mean (±SEM)
voltage dependence of steady-state inactivation and activation,
respectively. The V1/2 value of cells treated with 10 μM (R)-9 of
−76.5 ± 0.6 (n = 5) was signigifantly greater than that of control
(0.1% DMSO) cells (−63.8 ± 0.4 (n = 4); p < 0.05, Student’s t test).
The V1/2 and k of steady-state fast inactivation or steady-state fast
activation were not diﬀerent among any of the other compounds
tested (p > 0.05, one-way ANOVA). Data from n = 3−7 cells per
condition.
Figure 4. Eﬀect on frequency (use)-dependent block by the chimeric
compounds (R)-7−(R)-10 on Na+ currents in CAD cells. (A)
Frequency dependence of block was examined by holding cells at
the hyperpolarized potential of −80 mV and evoking currents at 10 Hz
by 20 ms test pulses to −10 mV (inset middle). Summary of average
frequency (use)-dependent decrease in current amplitude over time
(±SEM) produced by control (0.1% DMSO) or by the presence of 10
μM of the indicated compounds are shown (p > 0.05, one-way
ANOVA with Dunnett’s post hoc test). (B) Summary of the maximal
decrement in current amplitude observed at the 30th pulse for control
(0.1% DMSO) or the indicated compounds. (R)-9 and (R)-10 caused
a signiﬁcant decrease in current amplitude compared with control (*p
< 0.05, one-way ANOVA with Dunnett’s post hoc test; n = 5−8 cells).
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formation in response to an inactivation voltage protocol.
Voltage-gated sodium channel availability was conditioned by 5
s prepulses between −100 and +20 mV in 10 mV incre-
ments.23,34 Channels that undergo fast inactivation but not slow
inactivation are allowed to recover during a 1 s pulse to −70
mV before available current is measured at −10 mV for 20 ms.
(Figure 6A, left). Hyperpolarization allowed the channels to
recover from fast inactivation while limiting recovery from slow
inactivation. Diﬀerences in available current between control
and compound treated cells represent altered sodium channel
inactivation via either altered transition into slow-inactivated
state or block of fast-inactivated channels with slow oﬀ
kinetics.29,30 As before, here we did not distinguish between
these possibilities; however, both have the same physiological
outcome on generation of Na+ currents. Representative traces
from cells in the absence and presence of 10 μM (R)-4 and
(R)-10 are shown in Figure 6A (right). Full inactivation curves
for control (0.1% DMSO) and (R)-4 are shown in Figure 6B.
At −50 mV for the control (0.1% DMSO)-treated cells, 0.79 ±
0.06 fractional units (n = 5) of the Na+ current was available
and suggested a small fraction (i.e., 0.21 ± 0.06; calculated as 1
minus the normalized INa) of the channels entered inactivated
conformational states. This can be compared to (R)-4 (Figure
6B,C), where a large fraction (0.63 ± 0.13) underwent
inactivation. In addition to (R)-4, chimeric compounds (R)-1
and (R)-5−(R)-10 signiﬁcantly enhanced sodium channel
inactivation with maximal eﬀects in response to (R)-9 (0.92
± 0.09, n = 5) and (R)-10 (0.91 ± 0.05, n = 5) (p < 0.01,
Mann−Whitney U test). The rank order of chimeric compound
eﬀectiveness for promoting inactivation in the cortical neurons
mirrored the IC50 values obtained in CAD cells, with the
chlorine and triﬂoromethoxy-group substituted derivatives
Figure 5. Eﬀect of (S)-3 on sodium channel properties in CAD cells. (A, D, G) Voltage protocols for examining inactivation, fast inactivation, steady-
state activation, and frequency (use)-dependent block. (B, E, H) Representative current traces from CAD cells in the absence (control, 0.1% DMSO)
or presence of 100 μM (S)-3. (B) Solid and black dashed traces represent the currents induced at −120 and −50 mV, respectively (−50 mV step
highlighted in the voltage protocol). (C) Summary of the inactivation curves for CAD cells treated with 0.1% DMSO (control) or 0.5−200 μM (S)-
3. The concentrations of half maximal eﬀect for −50 mV conditioning pulse (see text for detailed explanations), the IC50, is indicated. (E)
Representative current traces (top, fast inactivation; bottom, steady-state activation). (F) Representative Boltzmann ﬁts for steady-state fast
inactivation and steady-state activation for CAD cells treated with 0.1% DMSO (control) or 10−200 μM of (S)-3. Values for V1/2, the voltage of half-
maximal inactivation and activation, and the slope factors (k) were derived from Boltzmann distribution ﬁts to the individual recordings and were
averaged to determine the mean (±SEM) voltage dependence of steady-state inactivation and activation, respectively. Statistically signiﬁcant
diﬀerences between ﬁts of fast inactivation from control cells (0.1% DMSO) compared to 10−200 μM of (S)-3 are indicated by the asterisks (*, p <
0.05, one-way ANOVA). (H) Representative overlaid traces are illustrated by pulses 1 and 30 for control (predrug) and in the presence of (S)-3
(100 μM). (I) Summary of average frequency (use)-dependent decrease in current amplitude over time (±SEM) produced by control (0.1%
DMSO) or 100 μM (S)-3. Data are from 4−13 cells per condition.
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((R)-7−(R)-10) being more potent than the unsubstituted
compound ((R)-4) or the three ﬂuorine substituted analogues
((R)-1, (R)-5, (R)-6). When (R)-2 and (S)-3 were tested at 10
μM with cortical neurons, neither parent compound aﬀected
inactivation, indicating that this concentration was insuﬃcient
to facilitate sodium channel inactivation in these cells (Figure
6C).
We then asked if the eight chimeric compounds could
enhance steady-state fast inactivation. Fast-inactivated state was
induced by the previously described elecrophysiological voltage
protocol, and data were ﬁtted to Boltzmann equations to derive
V1/2 value of fast inactivation and slope, k (Figure 7, top
left).34,36 The inactivation V1/2 for 0.1% DMSO-treated cells
was −53.2 ± 1.1 mV (n = 4), which diﬀered signiﬁcantly from
(R)-7- (−60.0 ± 2.1 mV; n = 5), (R)-8- (−57.9 ± 0.7 mV; n =
7), and (R)-10- (−58.4 ± 1.0 mV; n = 8) treated cells (p < 0.05
vs control; Student’s t-test; Figure 7). By comparison, we did
not see evidence that the remaining chimeric compounds
aﬀected V1/2 or k values of steady-state fast inactivation (Figure
7). At 10 μM, neither (R)-2 nor (S)-3 aﬀected fast inactivation
(Figure 7).
Next, we tested whether the chimeric compounds could alter
the voltage-dependence of sodium channel activation in cortical
neurons. Changes in activation for the cortical neurons treated
with the compounds were analyzed by comparison of
Boltzmann curve derived values V1/2 and slope k (Figure 7,
top right).23,34 The steady-state activation V1/2 for 0.1%
DMSO-treated (control) neurons was −27.4 ± 1.6 mV (n =
5). Four compounds, (R)-4 (−36.3 ± 4.9 mV; n = 5), (R)-5
(−37 ± 4.4 mV; n = 5), (R)-6 (−32.2 ± 1.9 mV; n = 4), and
(R)-7 (−40.4 ± 6.8 mV; n = 5) (p < 0.05 vs control; Student’s t
test; Figure 7), displayed signiﬁcant hyperpolarized shifts.
Correspondingly, neither 10 μM (R)-2 nor 10 μM (S)-3
aﬀected the steady-state activation of VGSCs (Figure 7).
Finally, we tested if the chimeric compounds could aﬀect
frequency (use)-dependent block of Na+ currents in cortical
neurons. Thirty repeated test pulses were applied in rapid
succession at 10 Hz (Figure 8A).23 The diﬀerence in available
current was measured by comparing peak current recorded
during each pulse and plotted as a fraction compared to the
current recorded at the initial pulse ((pulsen)/(pulse1)).
Representative currents are illustrated for control (0.1%
DMSO) and 10 μM (R)-10-treated cells (Figure 8B). Of the
eight chimeric compounds tested, (R)-9 and (R)-10 displayed
signiﬁcant frequency (use)-dependent inhibition (Figure 8C);
peak current recorded at the ﬁnal pulse was reduced by ∼35%
in the presence of 10 μM (R)-9 and ∼31% in the presence of
10 μM (R)-10 compared with control. A comparable ﬁnding
was observed in CAD cells (Figure 4). At 10 μM, neither of the
parent compounds ((R)-2, (S)-3) displayed frequency (use)-
inhibition of voltage-gated Na+ currents (Figure 8C).
Whole Animal Pharmacological Activity. The anti-
convulsant activity37 for compounds (R)-7−(R)-10 in the MES
model12 (mice, ip; rats, po) and the psychomotor 6 Hz (32
mA) seizure test for therapy-resistant limbic seizures16 (mice,
ip) were determined at the Anticonvulsant Screening Program
(ASP) of the NIH’s National Institute of Neurological
Disorders and Stroke (NINDS). The data are summarized in
Table 1 along with similar results obtained for chimeric
compounds (R)-11 and (R)-4−(R)-6,1 parent compounds (R)-
22,13 and (S)-3,5 and the ASDs phenytoin,38 phenobarbital,38
and valproate.38 We report, where possible, the compounds’
Figure 6. Eﬀects of the chimeric compounds ((R)-1, (R)-4−(R)-10) and the parent compounds ((R)-2, (S)-3) on inactivation state of Na+ currents
in rat embryonic cortical neurons. (A) Inactivation voltage protocol. Currents were elicited by 5 s prepulses between −100 and +20 mV (in 10 mV
increments), and then fast-inactivated channels were allowed to recover for 1000 ms at a hyperpolarized pulse to −70 mV before testing for the
fraction of available channels for 20 ms at −10 mV. Finally, the fraction of channels available at −10 mV was analyzed. Representative current traces
from cortical neurons in the absence (control, 0.1% DMSO) or presence of 10 μM (R)-4 or (R)-10 are illustrated. The black and pink traces
represent the peak current evoked (between −100 to −80 mV and −50 mV, respectively (also highlighted in the voltage protocol as a dashed pink
line). (B) Summary of steady-state activation curves for neurons treated with 0.1% DMSO (control) or 10 μM (R)-4. For compounds that mediate
inactivation, (R)-4 shown, signiﬁcant enhancement of inactivation is evident by separation of the curves starting at −80 mV. (C) Summary of the
fraction of current available at −50 mV for neurons treated with 0.1% DMSO (control) or 10 μM of the indicated compounds. Asterisks (*) indicate
statistically signiﬁcant diﬀerences in fraction of current available between control (0.1% DMSO) and the indicated compounds (p < 0. 05, Student’s t
test; n = 5−6 cells per condition).
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50% eﬀective dose (ED50) values obtained in quantitative
screening evaluations, the median doses for 50% neurological
impairment (TD50) in either the rotorod test in mice
39 or the
behavioral toxicity assessment in rats,40 and the corresponding
protective index value (PI = TD50/ED50). Compounds (R)-7−
(R)-10 were evaluated in the subcutaneous Metrazol (scMet)
seizure model.41 No activity was observed at 300 mg/kg (data
not shown). Similar ﬁndings were found for (R)-1,1 (R)-2,2,13
and structurally related compounds,42 but (S)-3 did display
activity in this model (scMet ED50 = 27 mg/kg).
5 With the
promising activity observed for (R)-1 in the TNI pain model,1
we evaluated (R)-1, (R)-4, (R)-5, and (R)-7−(R)-10 in the
formalin pain model17 at the NINDS ASP, and (R)-7−(R)-10
in the TNI model14 at the Indiana University School of
Medicine.
A. Anticonvulsant Activity. Compounds (R)-7−(R)-10
exhibited excellent activity in the MES seizure model. The
ED50 values for (R)-7−(R)-10 in mice (ip) were 7.2−16 mg/
kg, and in rats (po) 9.8−39 mg/kg, which were similar to the
values observed for phenytoin,38 but higher than those for (R)-
22,13 and (S)-35 (ED50 (mice, ip, mg/kg): (R)-7, 16; (R)-8, 7.2;
(R)-9, 12; (R)-10, 8.3; (R)-2, 4.5; (S)-3, 4.1; phenytoin, 9.5.
ED50 (rat, po, mg/kg): (R)-7, 39; (R)-8, 17; (R)-9, 9.8; (R)-10,
20; (R)-2, 3.9; (S)-3, 12; phenytoin, 30). While no clear
structural patterns emerged for the chimeric compounds, we
found that replacing the terminal 3″-ﬂuorine substituent in (R)-
1 by either a 3″- or 4″-chlorine group provided compounds
with substantially higher PI values in mice (PI: (R)-1, 2.0; (R)-
7, 12; (R)-8, 6.8). Finally, (R)-7−(R)-10 exhibited potent
activity in the 6 Hz (32 mA) psychomotor seizure assay in mice
(ip) that compared favorably with (R)-11 and (R)-213 (ED50
mice, ip, mg/kg: (R)-7, 13; (R)-8, 7.6; (R)-9, 12; (R)-10, 23;
(R)-1, ∼10; (R)-2, 10).
B. Formalin Pain Model. The formalin model has been
advanced as an eﬀective method to prescreen agents for
persistent clinical pain17 because of its ease of administration
and standardization. Administering formalin to mice leads to
biphasic changes of nociceptive behavior,43−45 with many
clinically used drugs for neuropathic pain being active in the
second (inﬂammation) phase of this model. In brief, mice are
given the test compound ip prior to the formalin (5%) injection
into a posterior paw. The formalin injection leads to paw
licking in control animals, and possibly the test animals, and
then the licking time is counted in 5 min bins.
Compounds (R)-1, (R)-4, (R)-5, and (R)-7−(R)-10 were
evaluated at a single dose (5−12 mg/kg) based, in part, on the
MES ED50 (mice, ip) values. Compounds (R)-1, (R)-4, (R)-5,
(R)-7, and (R)-10 administration led to signiﬁcant decreases in
the percent licking time (49−72% of control) in the second
(inﬂammation) phase of the model (Table 2), suggesting that
these compounds may be eﬀective in controlling neuropathic
pain. The compounds also showed activity in the ﬁrst (acute)
phase of the test (39−72% of control). Of the chimeric
compounds tested, only (R)-8 and (R)-9 did not show activity
in this model; we did not examine (R)-2 and (S)-3, but
previous studies reported that (R)-2 was eﬀective in the second
(inﬂammation) phase at 8 mg/kg.46
C. Tibial-Nerve Injury (TNI) Model. Next, we examined the
eﬀects of (R)-7−(R)-10 on chronic nociceptive behavior in an
animal model of TNI-mediated neuropathic pain (Figure 9A).14
Presurgical response to tactile stimulus evoked hindpaw
Figure 7. Eﬀects of the chimeric compounds ((R)-1, (R)-4−(R)-10)
and the parent compounds ((R)-2, (S)-3) on fast inactivation and
steady-state activation states of Na+ currents in rat embryonic cortical
neurons. Voltage protocol for fast inactivation (top left) and steady-
state activation (top right). Representative Boltzmann ﬁts for steady-
state fast inactivation and steady-state activation for cortical neurons
treated with 0.1% DMSO (control) and various concentrations of the
indicated compounds are shown. Values for V1/2, the voltage of half-
maximal inactivation and activation, and the slope factors (k) were
derived from Boltzmann distribution ﬁts to the individual recordings
and averaged to determine the mean (±SEM) voltage dependence of
steady-state inactivation and activation, respectively. Statistically
signiﬁcant diﬀerences between control and fast inactivation or
steady-state activation are indicated by the asterisks in symbol key
(*p < 0.05, one-way ANOVA; n = 5−7 cells per condition).
Figure 8. Eﬀects of the chiral compounds ((R)-1, (R)-4−(R)-10) and
the parent compounds ((R)-2, (S)-3) on frequency (use)-dependent
block of Na+ currents in rat embryonic cortical neurons. (A)
Frequency (use)-dependence of block was examined by holding cells
at the hyperpolarized potential of −80 mV and evoking currents at 10
Hz by 20 ms test pulses to −10 mV. (B) Representative overlaid traces
are illustrated by pulses 1 (black) and 30 (dashed) for control (0.1%
DMSO) and in the presence of (R)-10 (10 μM). (C) Summary of the
maximal decrement in current amplitude observed at the end of the
30th pulse train for control or 10 μM of the indicated compounds.
(R)-9 and (R)-10 caused a signiﬁcant decrease in current amplitude
compared with control (0.1% DMSO) (*p < 0.05, one-way ANOVA
with Dunnett’s post hoc test; n = 4−6 cells per condition).
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withdrawal at 70.7 ± 3.1 mN force (n = 6). Drug candidates
administered systemically to uninjured animals failed to
produce a change in the paw withdrawal threshold (data not
shown). Two weeks after TNI, animals exhibited pronounced
mechanical allodynia (31.1 ± 2.4 mN; n = 6) in response to
von Frey hair stimulation of the injured hindpaw. Compared
with postinjury baseline behavioral measurements, we observed
pronounced reversal of tactile hypersensitivity 1 h after
systemic administration of (R)-7 (10 mg/kg, ip) (∼89%)
(Figure 9B). Signiﬁcant reversal of hypersensitivity was also
observed 4 h after systemic injection of (R)-7 (43% of preinjury
values). In contrast, systemic administration of (R)-8−(R)-10
was ineﬀective at reducing hypersensitivity (n = 5−6). By
comparison, we reported that after the systemic administration
of (R)-1 (10 mg/kg, ip) the near complete reversal of tactile
hypersensitivity lasted ∼4 h.11 Correspondingly, (R)-2
signiﬁcantly reduced tactile hypersensitivity (∼72% of preinjury
values 1 h after administration), and (S)-3 showed no eﬀect
(Figure 9). The ASD carbamazepine (CBZ; 65 mg/kg, ip) was
ineﬀective (Figure 9B).
■ DISCUSSION
The chimeric compounds (R)-1 and (R)-4−(R)-10 were
designed by merging structural units present in (R)-2 and
(S)-3,1 anticonvulsant agents reported to modulate sodium
channels (Figure 1).7−10 We and others have shown that (R)-2
enhances the inactivation phase of neuronal VGSCs in response
to long (5 s) depolarizations without aﬀecting response to
standard fast inactivation protocols using briefer (500 ms)
depolarizations.7−9 Compound (R)-2 also inhibited Na+
currents in CAD cells in a frequency (use)-dependent fashion
at concentrations above the inactivation IC50 value.
23
Correspondingly, Salvati and co-workers showed that (S)-3
reduced whole-cell current density and reduced action potential
generation in response to repetative stimuli of cultured
hippocampal neurons.10 They did not test whether (S)-3
aﬀected VGSC slow inactivation. Thus, both (R)-2 and (S)-3
aﬀected Na+ currents, but the underlying kinetic modulation of
activation or inactivation for each compound may be diﬀerent.
We asked if the chimeric compounds (R)-1 and (R)-4−(R)-10
would display broader and possibly improved cellular and
whole animal pharmacological properties compared with either
(R)-2 or (S)-3.
The sodium channel properties of the chimeric compounds
reported herein were determined in a model cell line (i.e.,
CAD) as well as in cortical neurons. Direct comparison
between these two cell systems was diﬃcult. While the chimeric
compounds promoted inactivation, regardless of the cell type,
several compounds exhibited diﬀerences in modulation of
sodium channel fast inactivation (e.g., (R)-1, (R)-7−(R)-10),
steady-state activation (e.g., (R)-1, (R)-7), and frequency (use)-
inhibition of Na+ currents (e.g., (R)-1) in the two cell systems.
These diﬀerences may be the result of dissimilar channel
isoforms, expression levels of said isoforms, the species, the
auxiliary proteins in the two cell types, and the diﬀerent
concentrations of compounds used for each cell type.
Accordingly, direct comparisons of sodium channel kinetic
properties were restricted to data within the same cell type.
Neuronal hyperexcitability can be contolled by transitioning
VGSCs to the fast- and slow-inactivated conformations and by
constraining Na+ currents in a frequency (use)-dependent
manner.22 The chimeric compounds consistently aﬀected
sodium channel activity using voltage protocols designed to
aﬀect the slow inactivation pathway. Diﬀerences resolved by
this protocol, which subjects cells to 5 s depolarizations, can be
the result of either enhanced transition into slow-inactivated
Table 2. Pharmacological Activity of the Substituted (R)-N-
4-(Benzyloxy)benzyl 2-Acetamido-3-methoxypropionamide
Derivatives in the Formalin Pain Model
compd dose (mg/kg)a phase I (acute)b phase II (inﬂammatory)b
(R)-7 5.0 41 72
(R)-8 7.0 85 103
(R)-9 12 114 98
(R)-10 8.0 66 55
(R)-1 9.0 39 63
(R)-4 5.8 77 52
(R)-5 7.0 69 49
(R)-6 NDc
aCompounds administered to mice by ip. bPercent time spent licking
(s) of control. cND = not determined.
Figure 9. (R)-7 reverses mechanical hypersensitivity in the tibial-nerve
injury model of neuropathic pain. (A) Diagram of the sural, tibial, and
common peroneal terminal nerve branches of the sciatic nerve and
their dorsal root origins. Neuropathic painlike behavior was induced by
ligation of the tibial nerve and 2−4 mm of the nerve distal to the
ligation was removed. (B) Withdrawal threshold (in millinewtons,
mN) in response to von Frey stimulation to the paw ipsilateral to the
tibial-nerve injury following a single, intraperitoneal administration of
the indicated drugs (10 mg/kg, n = 5−6) on day 14 after injury. A
single injection of (R)-7 almost completely reversed tibial-nerve injury
induced mechanical hypersensitivity (p < 0.05; Student’s t test)
compared with predrug baseline. As a comparison, (R)-2 and (R)-1
also reversed mechanical hypersensitivity.11 Compound (S)-3 and the
antiseizure drug carbamazepine (CBZ) were without eﬀect.
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states, or transition into fast-inactivated state with slow drug oﬀ
rates.29,30 Enhanced transition to inactivated states in response
to this protocol is a favorable characteristic of ASDs. Using this
protocol, we found that the chimeric compounds with a
terminal substituted aryl group were 50−610-fold more
eﬀective than (R)-29,11 and 38−93-fold more eﬀective than
(S)-3 in transitioning CAD cells to inactivated states (Figure 2,
Table 1). We further showed that the chimeric compound’s
terminal X-substituent aﬀected inactivation activity, with the
triﬂuoromethoxy-group ((R)-9, (R)-10) being the most
eﬀective, then the chlorine substituent ((R)-7, (R)-8), and
last the ﬂuorine substituent ((R)-1, (R)-5). Finally, we found
that the 4″-substituted compounds were slightly more potent
than the 3″-substituted isomers. Compound (R)-10 was the
most potent agent (IC50 (μM): (R)-2, 85; (S)-3, 13; (R)-10,
0.14). We suggest that the enhanced potency for the chimeric
compounds compared with (R)-2 and (S)-3 was derived from
the synergy gained by judiciously combining, within a single
agent, key structural units (Figure 1, A and B) from two
compounds that show moderate inactivation properties.
Indeed, we have reported that N-(4′-((3′-ﬂuoro)benzyloxy)-
benzylamine25 (33), a compound that contained the biaryl
motif C found in the chimeric agents, transitioned CAD cells to
the inactivated state(s) (IC50 μM: (R)-1, 1.7; (R)-2, 85; (S)-3,
13; 33, 31). This result may explain why (S)-3, in part,
transitioned CAD cells to the inactivated state more eﬀectively
than (R)-2 because (S)-3 alone has an embedded biaryl C
motif.
Our determination that (S)-3 promoted inactivation of
VGSCs using both fast and slow inactivation protocols and
modestly inhibited CAD cells’ Na+ currents in a frequency
(use)-dependent manner aligned the electrophysiological
properties of this compound with the reported properties of
the corresponding 2″-ﬂuorine regioisomer, ralﬁnamide ((S)-
34).47 Stummann and co-workers have described the eﬀects of
(S)-34 on dorsal root ganglion Na+ currents. These researchers
found that (S)-34 produced a hyperpolarizing move in the
steady-state inactivation curve, aﬀected inactivation, and
exhibited frequency (use)-dependent inhibition of Na+
currents.
Among the chimeric compounds, we found that, in CAD
cells, compounds (R)-1, (R)-4, (R)-5, and (R)-9 aﬀected the
VGSC fast inactivation pathway, but (R)-7, (R)-8, and (R)-10
did not (Figure 3). When we tested the two parent compounds,
only (S)-3 promoted fast inactivation of VGSCs (Figure 5F).
Finally, we observed (R)-1, (R)-9, and (R)-10 repressed Na+
currents in a frequency (use)-dependent manner at concen-
trations above their inactivation IC50 values similar to (R)-2
22
and (S)-3 (Figure 5I) but that compounds (R)-4, (R)-5, (R)-7,
and (R)-8 did not (Figure 4). Thus, the chimeric compounds
all promoted VGSCs to inactivated conformations similar to
(R)-2 and (S)-3, but they displayed a range of fast inactivation
and frequency (use)-dependent inhibition properties.
We recently described the pharmacological activities of a set
of chimeric compounds, (R)-D, similar to (R)-1 and (R)-4−
(R)-10, in which a single bond separated the two terminal
aromatic rings,23 rather than the oxymethylene (OCH2) linkage
in the series described herein.23 Like the present series, (R)-D
contained a biaryl C motif (L = single bond).
For (R)-D, we prepared the ﬂuorine, chlorine, and
triﬂuoromethoxy-group derivatives where the X-substituent
was placed at either the 3″- or the 4″-position. When we
compared the CAD cell and rat embryonic cortical neuron data
for both series, we found similar results. Both potently
supported sodium channel inactivation, with the triﬂuorome-
thoxy-group compounds being the most eﬀective, followed by
the chlorine and then the ﬂuorine-substituted compounds. In
both series, some, but not all, compounds aﬀected fast
inactivation protocol results, and some compounds limited
Na+ currents in a frequency (use)-dependent manner. These
results suggested that the diﬀerent linkers (L = OCH2, single
bond) bridging the two aromatic rings did not markedly aﬀect
how these chimeric compounds modulated sodium channel
activity. The insensitivity of the composition and length of the
linker in the chimeric compound on VGSC inactivation was not
surprising. We obtained similar ﬁndings for the corresponding
biaryl-type amines E and F using rat embryonic cortical
neurons.20,36 These results are interesting, since the signiﬁcant
increase in inactivation observed for the chimeric compounds
compared with (R)-2 has been attributed, in part, to the
chimeric compound’s biaryl C motif and the enhanced
interaction of these compounds with the channel (receptor)
responsible for inactivation.25 These collective ﬁndings
reinforce the need for additional information concerning the
factors that govern this interaction and the apparent structural
latitude for the terminal biaryl C unit in the chimeric
compounds.
The enhanced potency of chimeric compounds (R)-1 and
(R)-4−(R)-10 to promote sodium channel inactivation
compared with (R)-2 and (S)-3 did not translate to an increase
in anticonvulsant activity for these agents over the parent
compounds. Rather, we observed that the chimeric compounds
((R)-4−(R)-10) were slightly less eﬀective in controlling
seizures in the MES model in mice (ip) than either (R)-22,13
or (S)-35 (ED50 mg/kg: (R)-1, 13; (R)-2, 4.5; (S)-3, 4.1; (R)-4,
5.8; (R)-5, 6.7; (R)-16, >10, <30; (R)-7, 16, (R)-8, 7.2; (R)-9,
12; (R)-10, 8.3). A parallel ﬁnding was seen in the MES test in
rats (po). We have not determined what accounts for this
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ﬁnding, but we recognize that multiple properties beyond the
interaction of the agent with the target site(s) determine
eﬃcacy in animal models. Similarly, cellular electrophysiological
studies do not fully recapitulate the anticonvulsant test events.
The data from the formalin pain model (Table 2) showed
that at low doses (5−9 mg/kg) most of the chimeric
compounds evaluated ((R)-1, (R)-4, (R)-5, (R)-7, (R)-10)
substantially reduced mouse discomfort in phase 2 (49−72% of
control) and phase 1 (39−77% of control) of the test. Only
(R)-8 and (R)-9 were ineﬀective in this model. Further support
for (R)-7′s pain-attenuating properties was gained by the
mechanical hypersensitivity reversal in the TNI model14
(Figure 9). The ﬁnding for (R)-7 mirrored that reported for
(R)-1.11 Structurally, these compounds are nearly identical with
the only diﬀerence being the 3″-halogen substituent ((R)-1, 3″-
F; (R)-7, 3″-Cl). Unlike the formalin model, the activity proﬁle
in the TNI test was sensitive to the terminal aromatic
substituent. Repositioning the chlorine moiety in (R)-7 or
replacing the chlorine moiety by a triﬂuoromethoxy group led
to complete loss of activity. Earlier, we suggested that (R)-1′s
strong eﬀects in promoting fast, and possibly slow, inactivation
in CAD cells was responsible for the reversal of tactile
hypersensitivity in the TNI model.11 Our ﬁnding that (R)-7 is
nearly as eﬀective as (R)-1 in this model and that (R)-2
administration also led to hypersensitivity reversal (Figure 9)
but that these compounds did not aﬀect fast inactivation in
CAD cells (Figure 3) places this hypothesis in doubt.
■ CONCLUSIONS
A select series of substituted (R)-N-(4′-(benzyloxy)benzyl 2-
acetamido-3-methoxypropionamides were prepared by merging
key units in (R)-2 and (S)-3 and positioning an electron-
withdrawing (Cl, OCF3) group at either the 3″- or 4″-site of
the terminal aromatic ring. The electrophysiological properties
documented that these compounds strongly transitioned
sodium channels to the inactivated state. The IC50 values of
CAD cells for (R)-7−(R)-10 were 250−610-fold more potent
than (R)-2 and 38−93-fold more potent than (S)-3. The
chimeric compounds’ high potency has been credited to the
strategic merger of units present in the two neurological
compounds (R)-2 and (S)-3. The chimeric compounds
displayed excellent anticonvulsant activities in animal seizure
models and promising activities in pain models.
■ METHODS
General Methods. The general methods employed in this study
were the same as those previously reported,2 and are summarized in
the Supporting Information. Compounds were checked by TLC, 1H
and 13C NMR, MS, and either HR-MS or elemental analysis. For all
new compounds evaluated in the pharmacological models, elemental
analysis was obtained. The TLC, NMR, and analytical data conﬁrmed
the purity of the ﬁnal products was ≥95%.
General Procedure for the Deprotection and Acetylation of
(R)-Substituted N-Benzyl 2-N-(tert-Butoxycarbonyl)amino-3-
methoxypropionamide Derivatives (Method 1). The N-(tert-
butoxycarbonyl compound was dissolved in CH2Cl2 (0.1−0.3 M) and
then treated with 4 M HCl in dioxane (3−4 equiv) at room
temperature (2−12 h). The mixture was concentrated in vacuo, and
the residue dissolved in CH2Cl2 (0.1−0.3 M) and then triethylamine
(2−3 equiv) and acetyl chloride (1.0−1.2 equiv) were carefully added
(0 °C). The resulting solution was stirred at room temperature (2−16
h), and then successively washed with an aqueous 10% citric acid
solution and a saturated aqueous NaHCO3 solution. The organic layer
was dried (Na2SO4) and concentrated in vacuo. The residue was
puriﬁed by column chromatography on SiO2 and/or recrystallized with
EtOAc/hexanes.
Preparation of (R)-N-4′-(3″-Chlorobenzyloxy)benzyl 2-Acet-
amido-3-methoxypropionamide ((R)-7). Employing Method 1,
(R)-29 (8.18 g, 18.3 mmol), 4 M HCl (15.98 mL, 63.9 mmol), Et3N
(5.60 mL, 40.2 mmol), and AcCl (1.42 mL, 20.1 mmol) gave (R)-7 as
a white solid (5.86 g, 82%): Rf = 0.40 (MeOH/CH2Cl2 1/20); mp
170−172 °C; [α]26D −18.1° (c 1.2, CHCl3). IR (nujol) 3282, 3082,
2923, 2860, 1634, 1551, 1456, 1378, 1246, 1130, 1058, 980, 777, 716
cm−1. 1H NMR (CDCl3) δ 2.00 (s, C(O)CH3), 3.35 (s, OCH3),
3.42−3.46 (m, CHH′OCH3), 3.77 (dd, J = 4.0, 9.0 Hz, CHH′OCH3),
4.32−4.43 (m, CH2N), 4.53−4.58 (m, CH), 5.01 (s, OCH2), 6.55 (d,
J = 6.4 Hz, NHCH), 6.83−6.91 (m, 2 ArH, NHCH2), 7.18 (d, J = 8.4
Hz, 2 ArH), 7.26−7.42 (m, 4 ArH); addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-7 gave only one signal
for the acetyl methyl and one signal for the ether methyl protons. 13C
NMR (CDCl3) δ 23.4 (C(O)CH3), 43.2 (NCH2), 52.6 (OCH2CH),
59.2 (OCH3), 69.4 (OCH2), 72.0 (OCH2CH), 115.2, 125.5, 127.6,
128.3, 129.1, 130.1, 130.8, 134.7, 139.2, 158.0 (ArC), 170.1, 170.5 (2
C(O)). LRMS (ESI+) 413.2 [M + Na]+ (calcd for C20H23ClN2O4Na
+
413.2). Anal. Calcd for C20H23ClN2O4: C, 61.46; H, 5.93; Cl, 9.07; N,
7.17. Found: C, 61.55; H, 5.97; Cl, 8.89; N, 7.17.
Preparation of (R)-N-4′-(4″-Chlorobenzyloxy)benzyl 2-Acet-
amido-3-methoxypropionamide ((R)-8). Employing Method 1,
(R)-30 (4.80 g, 10.7 mmol), 4 M HCl (9.38 mL, 37.5 mmol), Et3N
(3.28 mL, 23.5 mmol), and AcCl (0.83 mL, 11.8 mmol) gave (R)-8 as
a white solid (3.65 g, 87%): Rf = 0.40 (MeOH/CH2Cl2 1/20); mp
180−181 °C; [α]26D −17.9° (c 1.1, CHCl3). IR (nujol) 3280, 3103,
2924, 2859, 1635, 1553, 1458, 1375, 1240, 1098, 1047, 815, 727, 608
cm−1. 1H NMR (CDCl3) δ 1.99 (s, C(O)CH3), 3.35 (s, OCH3),
3.42−3.46 (m, CHH’OCH3), 3.76 (dd, J = 4.0, 9.0 Hz, CHH’OCH3),
4.31−4.42 (m, CH2N), 4.54−4.59 (m, CH), 5.00 (s, OCH2), 6.58 (d,
J = 6.4 Hz, NHCH), 6.85−6.92 (m, 2 ArH, NHCH2), 7.17 (d, J = 8.0
Hz, 2 ArH), 7.34 (s, 4 ArH); addition of excess (R)-(−)-mandelic acid
to a CDCl3 solution of (R)-8 gave only one signal for the acetyl methyl
and one signal for the ether methyl protons. 13C NMR (CDCl3) δ 23.3
(C(O)CH3), 43.2 (NCH2), 52.6 (OCH2CH), 59.2 (OCH3), 69.4
(OCH2), 72.1 (OCH2CH), 115.2, 128.9, 128.9, 129.0, 130.7, 133.9,
135.6, 158.1 (ArC), 170.1, 170.5 (2 C(O)). LRMS (ESI+) 391.2 [M +
H]+ (calcd for C20H23ClN2O4H
+ 391.2). Anal. Calcd for
C20H23ClN2O4: C, 61.46; H, 5.93; Cl, 9.07; N, 7.17. Found: C,
61.75; H, 5.86; Cl, 9.15; N, 7.11.
Preparation of (R)-N-4′-(3″-Triﬂuoromethoxybenzyloxy)-
benzyl 2-Acetamido-3-methoxypropionamide ((R)-9). Employ-
ing Method 1, (R)-31 (4.50 g, 9.0 mmol), 4 M HCl (7.90 mL, 31.6
mmol), Et3N (2.77 mL, 19.9 mmol), and AcCl (0.70 mL, 9.9 mmol)
gave (R)-9 as a white solid (3.50 g, 88%): Rf = 0.40 (MeOH/CH2Cl2
1/20); mp 139−140 °C; [α]26D −15.1° (c 1.0, CHCl3); IR (nujol)
3281, 3081, 2924, 2860, 1632, 1550, 1456, 1381, 1281, 1141, 1060,
974, 822, 710, 618 cm−1. 1H NMR (CDCl3) δ 1.98 (s, C(O)CH3),
3.35 (s, OCH3), 3.43−3.47 (m, CHH′OCH3), 3.76 (dd, J = 4.0, 9.2
Hz, CHH′OCH3), 4.32−4.43 (m, CH2N), 4.56−4.61 (m, CH), 5.04
(s, OCH2), 6.63 (d, J = 6.8 Hz, NHCH), 6.89−6.97 (m, 2 ArH,
NHCH2), 7.18 (d, J = 8.4 Hz, 2 ArH), 7.29−7.42 (m, 4 ArH), addition
of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-9 gave
only one signal for the acetyl methyl and one signal for the ether
methyl protons. 13C NMR (CDCl3) δ 23.3 (C(O)CH3), 43.1
(NCH2), 52.7 (OCH2CH), 59.2 (OCH3), 69.2 (OCH2), 72.1
(OCH2CH), 115.2, 119.3, 120.4 (ArC), 120.6 (q, J = 256.4 Hz,
OCF3), 125.6, 129.1, 130.1, 130.9, 139.5, 149.6, 158.0 (ArC), 170.1,
170.5 (2 C(O)). LRMS (ESI+) 441.1 [M + H]+ (calcd for
C21H23F3N2O5H
+ 441.1). Anal. Calcd for C21H23F3N2O5: C, 57.27;
H, 5.26; F, 12.94; N, 6.36. Found: C, 57.08; H, 5.20; F, 12.88; N, 6.30.
Preparation of (R)-N-4′-(4″-Triﬂuoromethoxybenzyloxy)-
benzyl 2-Acetamido-3-methoxypropionamide ((R)-10). Em-
ploying Method 1, (R)-32 (3.68 g, 7.4 mmol), 4 M HCl (6.47 mL,
25.9 mmol), Et3N (2.27 mL, 16.3 mmol), and AcCl (0.58 mL, 8.1
mmol) gave (R)-10 as a white solid (3.10 g, 95%): Rf = 0.40 (MeOH/
CH2Cl2 1/20); mp 172−173 °C; [α]26D −16.0° (c 1.1, CHCl3); IR
(nujol) 3281, 3102, 2923, 2860, 1635, 1552, 1457, 1378, 1275, 1233,
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1148, 1021, 835, 730, 609 cm−1. 1H NMR (CDCl3) δ 1.99 (s,
C(O)CH3), 3.35 (s, OCH3), 3.43−3.47 (m, CHH′OCH3), 3.76 (dd, J
= 4.0, 9.2 Hz, CHH′OCH3), 4.32−4.43 (m, CH2N), 4.56−4.60 (m,
CH), 5.03 (s, OCH2), 6.61 (d, J = 6.4 Hz, NHCH), 6.89−6.94 (m, 2
ArH, NHCH2), 7.18 (d, J = 8.4 Hz, 2 ArH), 7.22 (d, J = 8.4 Hz, 2
ArH), 7.44 (d, J = 8.4 Hz, 2 ArH); addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-10 gave only one signal
for the acetyl methyl and one signal for the ether methyl protons. 13C
NMR (CDCl3) δ 23.3 (C(O)CH3), 43.1 (NCH2), 52.7 (OCH2CH),
59.2 (OCH3), 69.3 (OCH2), 72.0 (OCH2CH), 115.1 (ArC), 120.6 (q,
J = 255.7 Hz, OCF3), 121.3, 129.0, 129.1, 130.8, 135.8, 149.0, 158.1
(ArC), 170.1, 170.5 (2 C(O)). LRMS (ESI+) 441.1 [M + H]+ (calcd
for C21H23F3N2O5H
+ 441.1). Anal. Calcd for C21H23F3N2O5: C, 57.27;
H, 5.26; F, 12.94; N, 6.36. Found: C, 57.35; H, 5.28; F, 12.78; N, 6.38.
Pharmacology. Compounds were screened under the auspices of
the NINDS’ ASP. Experiments were performed in male rodents
(albino Carworth Farms No. 1 mice (ip), albino Sprague−Dawley rats
(ip, po)). Housing, handling, and feeding complied with recom-
mendations contained in the Guide for the Care and Use of
Laboratory Animals. Anticonvulsant activity was determined using the
MES test,12 6 Hz,16 and the scMet test,41 and pain-attenuating activity
using the formalin test17 according to previously reported methods.1,2
Tibial-Nerve Injury. Pathogen-free, adult female Sprague−Dawley
(S/D) rats (150−200 g; Harlan Laboratories, Madison, WI) were
housed in temperature (23 ± 3 °C) and light (12 h light/12 h dark
cycle; lights on at 07:00 h) controlled rooms with standard rodent
chow and autoclaved tap water available. Experiments were performed
during the light cycle. Animals were randomly assigned to the
treatment groups. All animal experiments were approved by the
Institutional Animal Care and Use Committees of Indiana University
School of Medicine. All procedures were conducted in accordance
with the Guide for Care and Use of Laboratory Animals published by
the NIH and the ethical guidelines established by the International
Association for the Study of Pain.
To model neuropathic pain, we performed a tibial-nerve injury
(TNI) as previously described.11,14,48,49 Under anesthesia, rodents
were subjected to a tibial nerve ligation with 5−0 silk and the nerve
transected distal to the ligation. In addition, removal of 2−4 mm of
distal nerve stump prevented reinnervation by the proximal nerve. The
overlying tissue layers of muscle and skin were sutured and animals left
to recover.
Mechanical threshold was tested before, during and following
administration of candidate coumpounds by an experimenter blinded
to treatment groups. Behavioral baseline measurements were collected
from at least 2 separate days prior to the surgery. The rats were then
tested once weekly after the surgery. The incidence of foot withdrawal
was measured as a function in response to mechanical indentation of
the plantar surface of each hind paw with custom Von Frey-type
ﬁlaments as described previously.50
Catecholamine A-Diﬀerentiated (CAD) Cells. CAD cells were
grown at 37 °C and in 5% CO2 (Sarstedt, Newton, NC) in Ham’s
F12/DMEM (GIBCO, Grand Island, NY), supplemented with 10%
fetal bovine serum (Sigma, St. Louis, MO) and 1% penicillin/
streptomycin (100% stocks, 10 000 U/mL penicillin G sodium and
10 000 μg/mL streptomycin sulfate).9,15 Cells were passaged every 3−
5 days at a 1:5 dilution.
Cortical Neurons. Rat cortical neuron cultures were prepared
from cortices dissected from embryonic day 19 brains exactly as
described.51,52
Electrophysiology. Whole-cell voltage clamp recordings were
performed at room temperature on CAD cells and cortical neurons
using an EPC 10 ampliﬁer (HEKA Electronics, Lambrecht/Pfalz
Germany). Electrodes were pulled from thin-walled borosilicate glass
capillaries (Warner Instruments, Hamden, CT) with a P-97 electrode
puller (Sutter Instrument, Novato, CA) such that ﬁnal electrode
resistances were 1−2 MΩ when ﬁlled with internal solutions. The
internal solution for recording Na+ currents contained (in mM): 110
CsCl, 5 MgSO4, 10 EGTA, 4 ATP Na2-ATP, 25 HEPES (pH 7.2,
290−310 mOsm/L). The external solution contained (in mM): 100
NaCl, 10 tetraethylammonium chloride (TEA-Cl), 1 CaCl2, 1 CdCl2, 1
MgCl2, 10 D-glucose, 4 4-AP, 0.1 NiCl2, 10 HEPES (pH 7.3, 310−315
mOsm/L). Whole-cell capacitance and series resistance were
compensated with the ampliﬁer. Series resistance error was always
compensated to be less than ±3 mV. Cells were considered only when
the access resistance was less than 3 MΩ. Linear leak currents were
digitally subtracted by −P/4 leak subtraction. Unless otherwise
speciﬁed, protocols were preformed with 3 s between the ending of
a voltage pulse and beginning of the next. Maximum current tested at
the end of each protocol veriﬁed that 3 s was suﬃcient to re-equilibrate
channel availability.
Data Acquisition and Analysis. Signals were ﬁltered at 10 kHz
and digitized at 10−20 kHz. Analysis was performed using Fitmaster
and origin8.1 (OriginLab Corporation, Northampton, MA). For
activation curves, conductance (G) through sodium channels was
calculated using the equation G = I/(Vm − Vrev), where Vrev is the
reversal potential, Vm is the membrane potential at which the current
was recorded, and I is the peak current. Activation and inactivation
curves were ﬁtted to a single-phase Boltzmann function G/Gmax = 1/{1
+ exp[(V − V50)/k]}, where G is the peak conductance, Gmax is the
ﬁtted maximal G, V50 is the half activation voltage, and k is the slope
factor. Additional details of speciﬁc pulse protocols are described in
the Results text or ﬁgure legends.
Statistical Analyses. Diﬀerences between means were compared
by either paired or unpaired, two-tailed Student’s t tests or an analysis
of variance (ANOVA), when comparing multiple groups (repeated
measures whenever possible). If a signiﬁcant diﬀerence was
determined by ANOVA, then a Dunnett’s or Tukey’s post hoc test
was performed. Data are expressed as mean ± SEM, with p < 0.05
considered as the level of signiﬁcance.
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